Navigation Links
Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Date:5/3/2012

MOUNTAIN VIEW, Calif., May 3, 2012 /PRNewswire/ -- Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering intensive ophthalmic research into vision-compromising comorbidities. The Centers for Disease Control and Prevention predicts that diabetic retinopathy will triple from 5.5 million in 2005 to 16.0 million in 2050. As diabetes is the leading cause of blindness in working age people, improved treatments are urgently needed. The presence of novel biopharmaceuticals as well as advancements in formulation technology has boosted the outlook for the U.S. retinal therapeutics market.

Analysis from Frost & Sullivan's (http://www.pharma.frost.com) U.S. Retinal Therapeutics Market research estimates revenues in the age-related macular degeneration (AMD) segment of the market to reach $2.26 billion by 2016. Revenues in the diabetic macular edema (DME) segment are expected to reach $455.2 million by 2016.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.

"While the cannibalization of Roche/Genentech profits (i.e., Avastin and Lucentis) may sound like a market challenge for that company versus a driver for the market, the very availability of these two highly effective, novel medications is expected to continue to drive this previously underserved market," said a Frost & Sullivan research analyst. "Moreover, the absence of laws and regulations permitting the manufacture of generic equivalents of biologics ensures that these therapies will remain under patent protection until 2019."

Developing therapies to treat diseases of the back of the eye is complex and, as a result, there is strong market opportunity for wet AMD drugs. The scope for wet AMD drugs such as Lucentis and Avastin is being further expanded by penetration into other back-of-the-eye conditions such as DME and retinal vein occlusion.

Another factor uplifting market prospects is the aging baby boomer population in the United States, which will create a demand upsurge for ophthalmics that improve, restore and preserve sight. Ease of use of therapy is also expected to be of considerable importance among this growing elderly patient base. This has opened up new avenues of opportunity for pharmaceutical and drug delivery companies, enabling a boost in their revenues.

Established treatment alternatives impede the success of new DME therapies. Although Lucentis may achieve its primary endpoint in its trials for DME, it is unlikely to achieve the same level of commercial success it did with wet AMD due to the cost and relative effectiveness of existing treatment options. Lucentis must demonstrate significant clinical efficacy to justify the costly monthly injections required to sustain visual acuity gains in the DME patient population.

Long, drawn out and costly clinical trials will deter new market entrants. In addition, difficulties in finding patients willing to participate in clinical trials and the lack of funds for costly and lengthy trials limit drug companies' abilities to introduce new products into the market. Several pharmaceutical and drug delivery companies are ramping up research efforts to improve the delivery of drugs to the back of the eye.

"Trends indicate that Avastin will remain the most-utilized pharmacologic therapy for the treatment of retinal vascular disease," said the research analyst. "By 2016, Regeneron is expected to supplant Roche/Genentech as the largest revenue contributor to the market."

U.S. Retinal Therapeutics Market is part of the Life Sciences Growth Partnership Service program, which also includes research in the following markets: Analysis of the United States Glaucoma Pharmaceuticals Market, Specialty Physicians Discuss their Opinions of the United States Biosimilars Market, Analysis of the United States Contract Manufacturing Outsourcing Market, Strategic Analysis of the U.S. Research Antibodies Market, and Analysis of the U.S. Clinical Laboratory Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

U.S. Retinal Therapeutics Market

N85D

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
3. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
4. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
5. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
6. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
7. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
8. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough
11. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
(Date:5/24/2016)...  NxStage Medical, Inc. (Nasdaq: NXTM ), ... care, today announced that Jeffrey H. Burbank , ... schedule of investor conferences. Where applicable, a webcast of ... .   ... Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... SuperCloset is proud to officially ... the day to day issues, struggles and obstacles veterans’ need to overcome in order ... Project provides active or retired military veteran(s) with a donated SuperCloset product based on ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent ... the demand for a sustainable product to aid in the rehabilitation process has steadily ... the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has now ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human interest stories, courtesy of leaders in ... trends and tech within the industry, from leading advocates and associations—namely Jones & ...
(Date:5/26/2016)... , ... May 26, 2016 , ... There are many ... Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the ... percent say grilling is their favorite way to cook a hot dog, far outpacing ...
Breaking Medicine News(10 mins):